Journal of medicinal and pharmaceutical chemistry 2011-11-10

4-nitrobenzyloxycarbonyl derivatives of O(6)-benzylguanine as hypoxia-activated prodrug inhibitors of O(6)-alkylguanine-DNA alkyltransferase (AGT), which produces resistance to agents targeting the O-6 position of DNA guanine.

Rui Zhu, Mao-Chin Liu, Mei-Zhen Luo, Philip G Penketh, Raymond P Baumann, Krishnamurthy Shyam, Alan C Sartorelli

Index: J. Med. Chem. 54(21) , 7720-8, (2011)

Full Text: HTML

Abstract

A series of 4-nitrobenzyloxycarbonyl prodrug derivatives of O(6)-benzylguanine (O(6)-BG), conceived as prodrugs of O(6)-BG, an inhibitor of the resistance protein O(6)-alkylguanine-DNA alkyltransferase (AGT), were synthesized and evaluated for their ability to undergo bioreductive activation by reductase enzymes under oxygen deficiency. Three agents of this class, 4-nitrobenzyl (6-(benzyloxy)-9H-purin-2-yl)carbamate (1) and its monomethyl (2) and gem-dimethyl analogues (3), were tested for activation by reductase enzyme systems under oxygen deficient conditions. Compound 3, the most water-soluble of these agents, gave the highest yield of O(6)-BG following reduction of the nitro group trigger. Compound 3 was also evaluated for its ability to sensitize 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine (laromustine)-resistant DU145 human prostate carcinoma cells, which express high levels of AGT, to the cytotoxic effects of this agent under normoxic and oxygen deficient conditions. While 3 had little or no effect on laromustine cytotoxicity under aerobic conditions, significant enhancement occurred under oxygen deficiency, providing evidence for the preferential release of the AGT inhibitor O(6)-BG under hypoxia.


Related Compounds

Related Articles:

Differential expression of miR200a-3p and miR21 in grade II-III and grade IV gliomas: evidence that miR200a-3p is regulated by O⁶-methylguanine methyltransferase and promotes temozolomide responsiveness.

2014-07-01

[Cancer Biol. Ther. 15(7) , 938-50, (2014)]

Formation and repair of pyridyloxobutyl DNA adducts and their relationship to tumor yield in A/J mice.

2012-10-15

[Chem. Res. Toxicol. 25(10) , 2167-78, (2012)]

Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth.

2015-01-01

[Mol. Cancer Ther. 14(1) , 111-9, (2015)]

Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type.

2012-05-01

[Arch. Dermatol. 148(5) , 613-20, (2012)]

MGMT inhibition restores ERα functional sensitivity to antiestrogen therapy.

2012-01-01

[Mol. Med. 18 , 913-29, (2012)]

More Articles...